174:
Tait, Dereck R.; Hatherill, Mark; Van Der Meeren, Olivier; Ginsberg, Ann M.; Van Brakel, Elana; Salaun, Bruno; Scriba, Thomas J.; Akite, Elaine J.; Ayles, Helen M.; Bollaerts, Anne; Demoitié, Marie-Ange; Diacon, Andreas; Evans, Thomas G.; Gillard, Paul; Hellström, Elizabeth; Innes, James C.;
45:
in 2018, but its development was stalled thereafter due to negotiations between GSK, which was uninterested in the late stage development of the vaccine candidate, and non-commercial backers. After almost two years, the company concluded an agreement with the
175:
Lempicki, Maria; Malahleha, Mookho; Martinson, Neil; Mesia Vela, Doris; Muyoyeta, Monde; Nduba, Videlis; Pascal, Thierry G.; Tameris, Michele; Thienemann, Friedrich; Wilkinson, Robert J.; Roman, François (19 December 2019).
41:
and funded by non-profits and governments due to the limited commercial potential of tuberculosis vaccines, which are mainly needed in poor countries. The vaccine candidate completed a
58:(the remaining around US$ 400 million). It is scheduled to begin in 2024 with results available in 2028. One issue in developing the vaccine is the need for bark extract from the tree
47:
149:
97:
229:
224:
65:
42:
69:
60:
98:"How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits"
198:
188:
131:
55:
51:
218:
123:
23:
31:
135:
203:
150:"Press Release: Funding Late-Stage Development of M72 TB Vaccine Candidate"
193:
176:
177:"Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis"
73:
38:
27:
124:"Promising tuberculosis vaccine gets US$ 550-million shot in the arm"
72:. This adjuvant is used by several other GSK vaccines—especially the
76:
that is more profitable—and GSK owns most of the world's supply.
48:
Bill & Melinda Gates
Medical Research Institute
30:for tuberculosis in more than a century after the
8:
91:
89:
26:vaccine. If approved, it would be the first
96:Barry-Jester, Anna Maria (4 October 2023).
202:
192:
85:
50:. The Phase III trial is funded by the
7:
154:Bill & Melinda Gates Foundation
14:
64:that is used in combination with
16:Experimental tuberculosis vaccine
54:(up to US$ 150 million) and the
181:New England Journal of Medicine
37:It was initially developed by
1:
122:Tozer, Lilly (28 June 2023).
246:
230:Drugs developed by GSK plc
136:10.1038/d41586-023-02171-x
43:Phase II clinical trial
66:monophosphoryl lipid A
225:Tuberculosis vaccines
194:10.1056/NEJMoa1909953
70:immunologic adjuvant
22:is an experimental
61:Quillaja saponaria
187:(25): 2429–2439.
237:
209:
208:
206:
196:
171:
165:
164:
162:
160:
146:
140:
139:
119:
113:
112:
110:
108:
93:
74:shingles vaccine
56:Gates Foundation
245:
244:
240:
239:
238:
236:
235:
234:
215:
214:
213:
212:
173:
172:
168:
158:
156:
148:
147:
143:
121:
120:
116:
106:
104:
95:
94:
87:
82:
17:
12:
11:
5:
243:
241:
233:
232:
227:
217:
216:
211:
210:
166:
141:
114:
84:
83:
81:
78:
52:Wellcome Trust
15:
13:
10:
9:
6:
4:
3:
2:
242:
231:
228:
226:
223:
222:
220:
205:
204:10044/1/74245
200:
195:
190:
186:
182:
178:
170:
167:
155:
151:
145:
142:
137:
133:
129:
125:
118:
115:
103:
99:
92:
90:
86:
79:
77:
75:
71:
67:
63:
62:
57:
53:
49:
44:
40:
35:
33:
29:
25:
21:
184:
180:
169:
157:. Retrieved
153:
144:
127:
117:
105:. Retrieved
101:
59:
36:
24:tuberculosis
19:
18:
159:18 November
107:18 November
32:BCG vaccine
219:Categories
102:ProPublica
80:References
20:M72/AS01E
39:GSK plc
28:vaccine
128:Nature
68:as an
161:2023
109:2023
199:hdl
189:doi
185:381
132:doi
221::
197:.
183:.
179:.
152:.
130:.
126:.
100:.
88:^
34:.
207:.
201::
191::
163:.
138:.
134::
111:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.